Xcout IntelHepion Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Hepion Pharmaceuticals, Inc. among pharmaceuticals companies — ranked by similarity to what Hepion Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Hepion Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. at a glance
Hepion Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in Morristown, United States. It is publicly listed (HEPA) with a market capitalisation of $11.8M. Xcout tracks 27 named people at Hepion Pharmaceuticals, Inc., including Gary S. Stetz (Interim Chief Executive Officer & Director).
Hepion Pharmaceuticals, Inc. leadership
- Gary S. StetzInterim Chief Executive Officer & Director
- Vincent LoPrioreExecutive Chairman
- Sharen PyatetskayaDirector of Investor Relations
- Gary StetzExecutive Officer
- Vincent LoPrioreExecutive Officer
- Anand ReddiDirector
21 more named people on record for Hepion Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Hepion Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Hepion Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Similar pharmaceuticals company
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Similar pharmaceuticals company
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Similar pharmaceuticals company
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Similar pharmaceuticals company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Similar pharmaceuticals company
Nika Pharmaceuticals Inc., a pharmaceutical enterprise headquartered in Henderson, Nevada, focuses on the creation of medications to address a broad spectrum of health conditions. Its research and development efforts target serious diseases including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. The company's product line features antiviral treatments and nutritional supplements, notably providing a specialized thymus nuclear glycoprotein for the management of HIV. Originally established in 2000, the organization was previously known as Centennial Growth Equities Inc. before adopting its current name, Nika Pharmaceuticals, Inc., in May 2022.
Similar pharmaceuticals company
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
Similar pharmaceuticals company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Similar pharmaceuticals company
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Similar pharmaceuticals company
SCOHIA PHARMA, Inc. is a clinical-stage specialty bioventure headquartered in Fujisawa, Japan. Established in 2017, the company focuses its research and development on lifestyle-related diseases including cardiovascular, metabolic, and renal disorders.
Similar pharmaceuticals company
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Similar pharmaceuticals company
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Hepion Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Hepion Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →